NCT07086924Recruiting
Genetic Variation in TRAF3IP2 (rs13190932)
Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate
Source: ClinicalTrials.gov · Last updated 25 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 18 Jul 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- South Valley University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07086924
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Jun 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently undergoing immunosuppressive or systemic therapies.
- Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).
Other illness
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
Other
- Pregnancy and lactation.
Who the study is looking for
- Patients aged 18 -70years .
- the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.
- Willingness to participate: Signed informed consent.
- Initiating methotrexate (MTX) therapy: For prospective cohort.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qena Hospital Coordinator of this site? Confirm its status | Qina | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.